BEYOND Pilot Study
NCT00893217 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71
Last updated 2009-11-09
Summary
The purpose of this study is to valuate safety and tolerability of Betaseron.
Conditions
- Multiple Sclerosis
- Relapsing-Remitting
Interventions
- DRUG
-
Betaseron (Interferon beta-1b, BAY86-5046)
250 mcg
- DRUG
-
Betaseron (Interferon beta-1b, BAY86-5046)
500 mcg
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-11-30
- Completion
- 2003-06-30
Countries
- United States
Study Locations
More Related Trials
-
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00206635 ·Status: COMPLETED
-
BAY86-5046 (Betaseron), Non Interventional Studies
NCT02121444 ·Status: COMPLETED
-
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
NCT03408093 ·Status: COMPLETED
-
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
NCT00185211 ·Status: COMPLETED ·Phase: PHASE3
-
RNF and Betaseron® Tolerability Study
NCT00428584 ·Status: COMPLETED ·Phase: PHASE3
-
BENEFIT Extension Study
NCT00544037 ·Status: COMPLETED
-
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
NCT02652091 ·Status: COMPLETED
-
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
NCT00206648 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
NCT00370071 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
NCT00317941 ·Status: COMPLETED ·Phase: PHASE4
-
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
NCT01031459 ·Status: COMPLETED
-
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
NCT02247310 ·Status: COMPLETED
-
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
NCT01795872 ·Status: COMPLETED ·Phase: PHASE4
-
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
NCT02937285 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
NCT00202995 ·Status: TERMINATED ·Phase: PHASE4
-
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
NCT04356339 ·Status: COMPLETED
-
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
NCT00928967 ·Status: COMPLETED
-
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
NCT03134573 ·Status: COMPLETED
-
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
NCT00492466 ·Status: COMPLETED ·Phase: PHASE4
-
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
NCT00493116 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
NCT00313976 ·Status: WITHDRAWN ·Phase: PHASE3
-
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
NCT01332019 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
NCT00906399 ·Status: COMPLETED ·Phase: PHASE3
-
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
NCT02234869 ·Status: WITHDRAWN ·Phase: PHASE4
-
Physical Disability in Patients Treated With Betaferon
NCT00873340 ·Status: COMPLETED